ストックスクリーナーアプリを入手
3.1304
5.83%
0.1804
前日終値:
$2.95
開ける：
$2.95
24時間の取引高:
7.59M
Relative Volume:
1.11
時価総額：
$748.27M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-1.4766
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
+7.66%
1か月 パフォーマンス:
+11.90%
6か月 パフォーマンス:
+266.00%
1年 パフォーマンス:
+26.40%
1日の値動き範囲:
$2.95
$3.1799
1週間の範囲:
$2.66
$3.1799
52週間の値動き範囲:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.13 | 699.35M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
121.58 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.855 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.25 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
475.30 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion stock rises after $90 million payment from Japan launch By Investing.com - Investing.com Australia
Esperion stock rises after $90 million payment from Japan launch - Investing.com
Is Esperion Therapeutics Inc. stock undervalued vs historical averages2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Esperion shares rise as Otsuka launches NEXLETOL in Japan - Investing.com India
Esperion shares rise as Otsuka launches NEXLETOL in Japan By Investing.com - Investing.com Australia
Esperion Partners with Otsuka to Launch NEXLETOL in Japan, Secures $90 Million Payment - Quiver Quantitative
Esperion (NASDAQ: ESPR) earns $90M with Otsuka's NEXLETOL launch in Japan market - Stock Titan
Is Esperion Therapeutics Inc. stock a safe investment in uncertain markets2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Will Esperion Therapeutics Inc. stock recover faster than marketTreasury Yields & Daily Profit Focused Screening - newser.com
Esperion: HLS Therapeutics (TSX:HLS) Secures Health Canada Clearance for NILEMDO® - Kalkine Media
Why Esperion Therapeutics Inc. is moving todayMarket Movement Recap & Expert Verified Movement Alerts - newser.com
Multi asset correlation models including Esperion Therapeutics Inc.Portfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersQuarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Esperion (NASDAQ: ESPR) to Present at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 yearsJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Esperion’s cholesterol drug Nilemdo receives Health Canada approval By Investing.com - Investing.com Nigeria
Esperion partner announces HLS Therapeutics received approval of Nilemdo for the reduction of LDL cholesterol in Canadians at risk of cardiovascular disease - MarketScreener
Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease - TradingView
HLS Therapeutics Receives Health Canada Approval to Market NILEMDO® for LDL-Cholesterol Reduction in Partnership with Esperion - Quiver Quantitative
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - The Manila Times
Esperion Partner HLS Therapeutics Announces Approval of - GlobeNewswire
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Relative strength of Esperion Therapeutics Inc. in sector analysisInflation Watch & Breakout Confirmation Alerts - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockRisk Management & Free Expert Verified Stock Movement Alerts - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fake2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Can volume confirm reversal in Esperion Therapeutics Inc.Swing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.July 2025 Macro Moves & Capital Protection Trading Alerts - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatTrend Reversal & Free Reliable Trade Execution Plans - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
Esperion Therapeutics Inc (ESPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Looker Benjamin | General Counsel |
Sep 17 '25 |
Sale |
2.80 |
6,267 |
17,573 |
393,670 |
| Koenig Sheldon L. | President and CEO |
Sep 17 '25 |
Sale |
2.79 |
28,427 |
79,254 |
1,518,831 |
| Halladay Benjamin | Chief Financial Officer |
Sep 17 '25 |
Sale |
2.81 |
7,046 |
19,785 |
474,862 |
3.23%
大文字化:
|
ボリューム (24 時間):